Does Private Equity Hurt or Improve Healthcare Value? New Evidence and Mechanisms
Minghong Yuan, Wen Wen, Indranil Bardhan

TL;DR
This study examines the impact of private equity investment on healthcare value, revealing overall declines but highlighting the moderating role of health IT sharing, especially between hospitals and ambulatory providers, in improving care quality and efficiency.
Contribution
It provides new evidence on how health information sharing moderates private equity's impact on healthcare value, emphasizing the importance of IT-enabled collaboration and data standards.
Findings
Overall healthcare value declines after PE investment.
Health IT sharing improves cost efficiency and care quality.
Hospital-ambulatory provider data sharing drives quality improvements.
Abstract
What is the impact of private equity (PE) investment on healthcare value? Does PE investment hurt or improve healthcare value, and if so, can its effect be mitigated through the use of health information technologies (IT)? Given the significant investments by PE firms in the healthcare sector in recent years, these are important research questions. Stakeholders, including policy makers, care providers, and patients, need to understand their likely impact and whether PE ownership is aligned with their interests. Using a staggered difference-in-differences approach and data from US hospitals from 2008-2020, we observe that the overall value of healthcare delivered by hospitals declines after PE investment. However, our empirical evidence reveals that IT-enabled, health information sharing plays an important moderating role. Hospitals with stronger information-sharing capabilities exhibit…
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHealthcare Policy and Management · Pharmaceutical Economics and Policy · Primary Care and Health Outcomes
